Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares. The stock had previously closed at $52.83.
Wall Street Analyst Weigh In
Separately, HC Wainwright raised Basilea Pharmaceutica to a "strong-buy" rating in a research note on Monday, September 23rd.
Check Out Our Latest Stock Report on BPMUF
Basilea Pharmaceutica Stock Performance
The business has a 50-day moving average price of $51.49 and a two-hundred day moving average price of $48.27.
About Basilea Pharmaceutica
(
Get Free Report)
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Further Reading
Before you consider Basilea Pharmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.
While Basilea Pharmaceutica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
